ReShape Lifesciences Announces Pricing of $2.6 Million Public Offering

ReShape Lifesciences

Announces Pricing of $2.6 Million Public Offering

Calif., Jun. 9, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ("ReShape"

or the "Company") (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company,

today announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share.

Gross proceeds from the offering are expected to be approximately $2.6 million before deducting placement agent fees and other offering

expenses. The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions.

Group LLC is acting as sole placement agent in connection with the offering.

public offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-287168), previously

filed with the U.S. Securities and Exchange Commission (the "SEC") on May 9, 2025 and subsequently declared effective

by the SEC on May 14, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering and describing

the terms thereof has been filed with the SEC and forms a part of the effective registration statement and is available on the SEC's

website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained by contacting Maxim

Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or by telephone at (212) 895-3745 or

by email at syndicate@maximgrp.com. The final terms of the Offering will be disclosed in a final prospectus supplement to be filed

with the SEC, which will be available for free on the SEC's website at www.sec.gov

press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor

shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful

prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

ReShape Lifesciences

Lifesciences is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of

proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band and Lap-Band 2.0

Flex Systems provide minimally invasive, long-term treatment of obesity and are an alternative to more invasive surgical stapling procedures

such as the gastric bypass or sleeve gastrectomy. The ReShape Diabetes Neuromodulation system (formerly, Diabetes Bloc-Stim Neuromodulation

(DBSN )) is a novel minimally invasive therapeutic implant concept that delivers bio-electronic neuromodulation of vagus nerve

branches that are innervating organs which regulate plasma glucose. The Obalon balloon technology is a non-surgical, swallowable,

gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.

Safe Harbor Statement

press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual

results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking

statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could,"

"may," "intend," "will," "continue," "future," other words of similar meaning and the

use of future dates. Factors that could cause actual results to differ materially from those discussed in the forward-looking statements

include, among other things statements regarding the completion of the offering and the satisfaction of customary closing conditions

related to the offering. These and additional risks and uncertainties are described more fully in the company's filings with the Securities

and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K

and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not

undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events

or otherwise, except as required by law.

Lifesciences Investor Contact:

and Chief Executive Officer

Communications Group